- Home
- STRO
STRO
Sutro Biopharma Inc.
as 04-18-2025 1:43pm EST
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 50.0M | IPO Year: | 2018 |
| Target Price: | $6.83 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.96 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.54 - $5.17 | Next Earning Date: | 05-12-2025 |
| Revenue: | $62,043,000 | Revenue Growth: | -59.64% |
| Revenue Growth (this year): | -22.49% | Revenue Growth (next year): | 1.29% |
Latest Sutro Biopharma Inc. News
STRO Breaking Stock News: Dive into STRO Ticker-Specific Updates for Smart Investing
TipRanks
a month ago
Reddit initiated, Netflix upgraded: Wall Street’s top analyst calls
MT Newswires
a month ago
HC Wainwright Downgrades Sutro Biopharma to Neutral From Buy, Price Target is $2
MT Newswires
a month ago
Oppenheimer Downgrades Sutro Biopharma to Market Perform From Outperform
MT Newswires
a month ago
Deutsche Bank Adjusts Sutro Biopharma Price Target to $5 From $10, Maintains Buy Rating
Simply Wall St.
a month ago
Sutro Biopharma Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
GlobeNewswire
a month ago
Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025
TipRanks
a month ago
Chipotle upgraded, Charter initiated: Wall Street’s top analyst calls
TipRanks
a month ago
Sutro Biopharma downgraded to Neutral from Overweight at Piper Sandler
Compare STRO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "STRO Sutro Biopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.